Literature DB >> 15919107

Cannabinoid tolerance and dependence: a review of studies in laboratory animals.

Sara González1, Maribel Cebeira, Javier Fernández-Ruiz.   

Abstract

Two are the issues on cannabis addiction that provoke more controversy from a research perspective. The first one is related to the development of tolerance phenomena and, in particular, of a dependence state after chronic cannabinoid consumption, with appearance of withdrawal signs when this is interrupted, that would be (or not) comparable to those observed for other drugs. A second controversial issue is related to the possibility that chronic cannabinoid consumption may increase the risk to consume other drugs of greater addictive power. Since the discovery in the 1990s of the endocannabinoid signaling system as the target for the action of plant-derived cannabinoids, many studies have addressed these two questions in laboratory animals and, although the results have resulted controversial in various aspects, the following conclusions seem evident: (i) prolonged exposure to plant-derived, synthetic or endogenous cannabinoid agonists in laboratory animals is currently associated with the development of tolerance for most of their pharmacological effects, (ii) tolerance is essentially due to adaptative phenomena consisting in pharmacodynamic events (down-regulation/desensitization of cannabinoid receptors), although some evidence exist on additional pharmacokinetic responses, (iii) the discontinuation of chronic cannabinoid treatment does not elicit abstinence responses spontaneously in most of the cases, presumably because the pharmacokinetic characteristics of cannabinoids, but these responses may be elicited after the blockade of cannabinoid CB1 receptors in cannabinoid-tolerant animals, (iv) these abstinent responses include mainly somatic signs and changes in various molecular processes affected during the abstinence to other drugs although the magnitude of these changes was currently lower in the case of cannabinoids, and (v) cannabinoid-tolerant animals do not appear to be more vulnerable to reinforcing properties of morphine, although the manipulation of the endocannabinoid signaling might serve to treat cannabis addiction and, in particular, the addiction to other drugs such as alcohol, nicotine or opioids. The present review article will address all these aspects trying to establish the bases for future research.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15919107     DOI: 10.1016/j.pbb.2005.01.028

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  77 in total

Review 1.  Animal models of cannabinoid reward.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

2.  Cannabinoid hyperemesis: a case series of 98 patients.

Authors:  Douglas A Simonetto; Amy S Oxentenko; Margot L Herman; Jason H Szostek
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

3.  BOLD responses to inhibition in cannabis-using adolescents and emerging adults after 2 weeks of monitored cannabis abstinence.

Authors:  Alexander L Wallace; Kristin E Maple; Alicia T Barr; Krista M Lisdahl
Journal:  Psychopharmacology (Berl)       Date:  2020-07-26       Impact factor: 4.530

4.  The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice.

Authors:  Elizabeth A Cairns; Anna-Maria Szczesniak; Alex J Straiker; Pushkar M Kulkarni; Roger G Pertwee; Ganesh A Thakur; William H Baldridge; Melanie E M Kelly
Journal:  J Ocul Pharmacol Ther       Date:  2017-07-18       Impact factor: 2.671

5.  Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia.

Authors:  Darryl T Hamamoto; Subhalakshmi Giridharagopalan; Donald A Simone
Journal:  Eur J Pharmacol       Date:  2006-12-09       Impact factor: 4.432

6.  Rapid CB1 cannabinoid receptor desensitization defines the time course of ERK1/2 MAP kinase signaling.

Authors:  Tanya L Daigle; Christopher S Kearn; Ken Mackie
Journal:  Neuropharmacology       Date:  2007-06-26       Impact factor: 5.250

Review 7.  The endocannabinoid system as a target for the treatment of cannabis dependence.

Authors:  Jason R Clapper; Regina A Mangieri; Daniele Piomelli
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

Review 8.  Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?

Authors:  William E Fantegrossi; Jeffery H Moran; Anna Radominska-Pandya; Paul L Prather
Journal:  Life Sci       Date:  2013-09-29       Impact factor: 5.037

9.  Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.

Authors:  Liting Deng; Josée Guindon; Benjamin L Cornett; Alexandros Makriyannis; Ken Mackie; Andrea G Hohmann
Journal:  Biol Psychiatry       Date:  2014-04-25       Impact factor: 13.382

10.  Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol.

Authors:  Marina Rubio; Douglas McHugh; Javier Fernández-Ruiz; Heather Bradshaw; J Michael Walker
Journal:  Neurosci Lett       Date:  2007-06-02       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.